Broker Revenue Forecasts For Danimer Scientific, Inc. (NYSE:DNMR) Are Surging Higher

Danimer Scientific, Inc. (NYSE:DNMR) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The analysts have sharply increased their revenue numbers, with a view that Danimer Scientific will make substantially more sales than they'd previously expected.

After this upgrade, Danimer Scientific's five analysts are now forecasting revenues of US$78m in 2024. This would be a substantial 68% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$70m in 2024. The consensus has definitely become more optimistic, showing a solid increase in revenue forecasts.

View our latest analysis for Danimer Scientific

There was no particular change to the consensus price target of US$1.51, with Danimer Scientific's latest outlook seemingly not enough to result in a change of valuation.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. It's clear from the latest estimates that Danimer Scientific's rate of growth is expected to accelerate meaningfully, with the forecast 68% annualised revenue growth to the end of 2024 noticeably faster than its historical growth of 9.1% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.3% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Danimer Scientific is expected to grow much faster than its industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They're also forecasting more rapid revenue growth than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Danimer Scientific.

Analysts are clearly in love with Danimer Scientific at the moment, but before diving in - you should be aware that we've identified some warning flags with the business, such as dilutive stock issuance over the past year. For more information, you can click through to our platform to learn more about this and the 3 other concerns we've identified .

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.